YU13902A - Mezoprogestini (progesteron receptor modulatori) kao komponente kontraceptivnih sredstava za žene - Google Patents

Mezoprogestini (progesteron receptor modulatori) kao komponente kontraceptivnih sredstava za žene

Info

Publication number
YU13902A
YU13902A YU13902A YUP13902A YU13902A YU 13902 A YU13902 A YU 13902A YU 13902 A YU13902 A YU 13902A YU P13902 A YUP13902 A YU P13902A YU 13902 A YU13902 A YU 13902A
Authority
YU
Yugoslavia
Prior art keywords
mesoprogestins
female
progesterone receptor
component
contraception
Prior art date
Application number
YU13902A
Other languages
English (en)
Serbo-Croatian (sh)
Inventor
Kristof Chwalisz
Walter Elger
Gerd Schubert
Original Assignee
Schering Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag. filed Critical Schering Ag.
Publication of YU13902A publication Critical patent/YU13902A/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
YU13902A 1999-08-31 2000-08-31 Mezoprogestini (progesteron receptor modulatori) kao komponente kontraceptivnih sredstava za žene YU13902A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38613399A 1999-08-31 1999-08-31

Publications (1)

Publication Number Publication Date
YU13902A true YU13902A (sh) 2006-01-16

Family

ID=23524305

Family Applications (1)

Application Number Title Priority Date Filing Date
YU13902A YU13902A (sh) 1999-08-31 2000-08-31 Mezoprogestini (progesteron receptor modulatori) kao komponente kontraceptivnih sredstava za žene

Country Status (28)

Country Link
EP (1) EP1605949A2 (pl)
JP (1) JP2003511399A (pl)
KR (1) KR20020038745A (pl)
CN (1) CN1384748A (pl)
AR (1) AR025455A1 (pl)
AU (1) AU781835B2 (pl)
BG (1) BG106441A (pl)
BR (1) BR0013711A (pl)
CA (1) CA2383650A1 (pl)
CO (1) CO5190694A1 (pl)
CZ (1) CZ2002707A3 (pl)
EA (1) EA006805B1 (pl)
EE (1) EE200200103A (pl)
HR (1) HRP20020265A2 (pl)
HU (1) HUP0202515A3 (pl)
IL (1) IL148415A0 (pl)
LT (1) LT5001B (pl)
LV (1) LV12940B (pl)
MX (1) MXPA02002186A (pl)
NO (1) NO20020998L (pl)
NZ (1) NZ517470A (pl)
PE (1) PE20010579A1 (pl)
PL (1) PL353994A1 (pl)
SI (1) SI20853A (pl)
SK (1) SK2982002A3 (pl)
UA (1) UA77150C2 (pl)
WO (1) WO2001026603A2 (pl)
YU (1) YU13902A (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE50304970D1 (de) * 2002-08-02 2006-10-19 Schering Ag Progesteronrezeptormodulatoren mit erhöhter antigonadotroper aktivität für die weibliche fertilitätskontrolle und hormonersatztherapie
DE10236405A1 (de) 2002-08-02 2004-02-19 Schering Ag Progesteronrezeptormodulatoren mit erhöhter antigonadotroper Aktivität für die weibliche Fertilitätskontrolle und Hormonersatztherapie
CA2524474A1 (en) * 2003-05-02 2004-11-18 Duramed Pharmaceuticals, Inc. Methods of hormonal treatment utilizing extended cycle contraceptive regimens
US20050215535A1 (en) * 2004-03-24 2005-09-29 Kristof Chwalisz Sequential SPRM/progestin treatment
SV2006002165A (es) * 2004-07-07 2006-05-09 Wyeth Corp Regimenes y kits de progestina ciclica ref. am101677
DE102005050729A1 (de) * 2005-10-19 2007-04-26 Schering Ag Verfahren zur präventiven bedarfsweisen hormonalen Kontrazeption
CA2757496A1 (en) 2009-04-14 2010-10-21 Andre Ulmann Method for on-demand contraception
CN110548034A (zh) * 2019-07-12 2019-12-10 广州莎蔓生物科技有限公司 一种怀孕阻断药物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2054271A (en) 1932-05-17 1936-09-15 Schering Kahlbaum Ag Production of crystallized hormone esters
DE699310C (de) 1936-11-20 1940-11-27 Chemische Ind Ges Verfahren zur Herstellung von in 3-Stellung veresterten Verbindungen vom Typus des Oestradiols
US2225419A (en) 1937-03-01 1940-12-17 Schering Corp Process for the conversion of 17-cisalcohols of the cyclopentanopolyhydrophenanthrene series into the corresponding 17-trans-alcohols
US2611773A (en) 1951-08-21 1952-09-23 Upjohn Co Estradiol 17-cyclopenetanepropionate
US2990414A (en) 1957-03-26 1961-06-27 Syntex Sa 17-undecenoate of estradiol
DE3337450A1 (de) 1983-10-12 1985-04-25 Schering AG, 1000 Berlin und 4709 Bergkamen Prostaglandine und antigestagene fuer den schwangerschaftsabbruch
NZ226316A (en) * 1987-09-24 1991-10-25 Jencap Research Ltd Pharmaceutical contraceptive preparations and packages containing from 20-35 unit dosages comprising an estrogen and a progestin; the unit dosages having alternating estrogen and progestin dominance
US5439913A (en) 1992-05-12 1995-08-08 Schering Aktiengesellschaft Contraception method using competitive progesterone antagonists and novel compounds useful therein
US5516769A (en) 1993-02-19 1996-05-14 The Medical College Of Hampton Roads Method of inhibiting fertilization
DE4332283A1 (de) 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4332284C2 (de) * 1993-09-20 1997-05-28 Jenapharm Gmbh 11-Benzaldoxim-17beta-methoxy-17alpha-methoxymethyl-estradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4429397C2 (de) 1994-08-09 2003-11-20 Jenapharm Gmbh Estra-1,3,5(10)-trien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
DE4447715C2 (de) 1994-08-09 1998-02-05 Jenapharm Gmbh Verwendung von Estra-1,3,5(10)-trien-Derivaten zur hormonalen Behandlung von Prostatakarzinomen
HU226566B1 (en) * 1994-10-24 2009-04-28 Schering Ag Use of competitive progesterone antagonists for producing pharmaceutical compositions for regulating female fertility as required
US6040340A (en) * 1996-05-07 2000-03-21 Schering Aktiengesellschaft Implantation rates after in vitro fertilization, treatment of infertility and early pregnancy loss with a nitric oxide donor alone or in combination with progesterone, and a method for contraception with nitric oxide inhibitors
DE69710896T2 (de) * 1996-06-25 2002-09-26 Akzo Nobel N.V., Arnhem Progestogen-anti-progestogen therapien
WO1998005679A2 (en) * 1996-08-05 1998-02-12 Duke University Mixed agonists of the progesterone receptor and assays therefor
DE19809845A1 (de) * 1998-03-03 1999-09-09 Jenapharm Gmbh S-substituierte 11beta-Benzaldoxim-estra-4,9-dien-kohlensäurethiolester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen
HK1043788A1 (zh) * 1999-05-04 2002-09-27 American Home Products Corporation 四環黃體酮受體調節劑化合物及方法

Also Published As

Publication number Publication date
WO2001026603A2 (en) 2001-04-19
JP2003511399A (ja) 2003-03-25
EA200200284A1 (ru) 2002-10-31
SK2982002A3 (en) 2002-07-02
LT2002035A (lt) 2002-10-25
CZ2002707A3 (cs) 2002-11-13
NO20020998D0 (no) 2002-02-28
CA2383650A1 (en) 2001-04-19
SI20853A (sl) 2002-10-31
AU3215001A (en) 2001-04-23
CN1384748A (zh) 2002-12-11
AR025455A1 (es) 2002-11-27
PL353994A1 (pl) 2003-12-15
NZ517470A (en) 2004-03-26
NO20020998L (no) 2002-03-14
WO2001026603A3 (en) 2002-01-17
UA77150C2 (en) 2006-11-15
HRP20020265A2 (en) 2004-02-29
BR0013711A (pt) 2002-05-07
EA006805B1 (ru) 2006-04-28
HUP0202515A3 (en) 2004-06-28
PE20010579A1 (es) 2001-06-04
MXPA02002186A (es) 2002-09-02
CO5190694A1 (es) 2002-08-29
IL148415A0 (en) 2002-09-12
KR20020038745A (ko) 2002-05-23
HUP0202515A2 (hu) 2002-12-28
BG106441A (bg) 2002-09-30
EP1605949A2 (en) 2005-12-21
EE200200103A (et) 2003-04-15
AU781835B2 (en) 2005-06-16
LV12940B (en) 2003-06-20
LT5001B (lt) 2003-03-25

Similar Documents

Publication Publication Date Title
WO1995011013A3 (de) Kombination von progesteronantagonisten und antiöstrogenen mit partialer agonistischer wirkung für die hormonsubstitutions-therapie für peri- und postmenopausale frauen
TW200607798A (en) Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof
TW200605882A (en) Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof
WO2002047693A3 (en) Steroid hormone products comprising a stabilizing agent in non-crystalline form
HUP0103345A3 (en) Use of estrogen receptor modulators in combination with sexual steroid precursors for the preparation of pharmaceutical compositions
WO2000066590A3 (en) Tetracyclic progesterone receptor modulator compounds and methods
CA2222133A1 (en) Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen
WO2004110408A3 (en) Process for the manufacture of stable shaped particles consisting of estradiol and cholesterol
CA2188907A1 (en) Combination compound for contraception based on natural estrogen
PL348113A1 (en) Drug delivery device, especially for the delivery of progestins and estrogens
UA37259C2 (uk) Активна речовина для одержання лікарських засобів при лікуванні дисфункціональних маткових кровотеч
YU13902A (sh) Mezoprogestini (progesteron receptor modulatori) kao komponente kontraceptivnih sredstava za žene
WO2000074649A3 (en) Ophthalmic histamine compositions and uses thereof
BG101427A (en) Competitive progesterone antagonists for regulating female fertility as required
EP1090639A3 (en) Pharmaceutical composition containing a progestational corticoid and a selective estrogen receptor modulator
WO2001015679A3 (en) Mesoprogestins for the treatment and prevention of benign hormone dependent gynecological disorders
WO1999020223A3 (en) Luteinising hormone antagonists useful for treatment of estrogen deficiencies, or as a contraceptive
WO2002056903A3 (en) Methods for treating hormone associated conditions using a combination of lhrh antagonists and specific estrogen receptor modulators
EA200601089A1 (ru) Трансдермальная доставка гормонов без необходимости использования агентов, усиливающих проникновение
WO2001034126A3 (en) Mesoprogestins (progesterone receptor modulators) as a component of compositions for hormone replacement therapy (hrt)
MXPA01011296A (es) Composiciones contraceptivas que contienen derivados de indolina y agentes progestacionales.
WO2003099322A3 (en) Il-11 derivatives and therapeutic uses thereof
WO1996028154A3 (de) Verwendung von antiestrogenen zur männlichen fertilitätskontrolle
BR0116127A (pt) Composto, composição farmacêutica, uso de um composto, e, conjunto para a contracepção masculina
Robb-Nicholson By the way, doctor. I am 47 and have been taking Loestrin 1/20 for the past seven months. After the first month, I ceased having periods, which my gynecologist says is typical. Could you comment on why this happens and whether I am putting myself at increased risk for uterine cancer?